Coleman RL et al. Overall survival results from ARIEL3: A phase 3 randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. IGCS 2022;Abstract 557.

DiSilvestro P et al. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: The SOLO1/GOG 3004 trial. J Clin Oncol 2022;41(3):609-17. Abstract

Glas M et al. The impact of tumor treating fields on glioblastoma progression patterns. Int J Radiat Oncol Biol Phys 2022;112(5):1269-78. Abstract

Lesser TH et al. Rh immune globulin after the transfusion of RhD-positive blood in a patient with a partial D antigen. Obstet Gynecol 2022;140(6):1052-5. Abstract

Li J et al. Tumor treating fields (TTFields) therapy plus XELOX chemotherapy for front line treatment of advanced unresectable gastroesophageal junction adenocarcinoma (GEJC) or gastric adenocarcinoma (GC): A multicenter phase II trial. ESMO Asia 2022;Abstract LBA3.

Monk BJ et al. A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). J Clin Oncol 2022;40(34):3952-64. Abstract

Ray-Coquard I et al. Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC). ESMO 2022;Abstract LBA29.

Shams S, Patel CB. Anti-cancer mechanisms of action of therapeutic alternating electric fields (tumor treating fields [TTFields]). J Mol Cell Biol 2022;14(8):mjac047. Abstract